inositol has been researched along with Dementia in 25 studies
Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.
inositol : Any cyclohexane-1,2,3,4,5,6-hexol.
1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.
muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.
Dementia: An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The mean CSF concentration and the mean CSF/plasma concentration ratio of myo-inositol were significantly elevated in Down syndrome compared with controls, but were not correlated with the presence of dementia in the Down subjects." | 9.08 | Polyol profiles in Down syndrome. myo-Inositol, specifically, is elevated in the cerebrospinal fluid. ( Holloway, HW; Rapoport, SI; Schapiro, MB; Shetty, HU, 1995) |
| "The aim of study was to search for new biomarkers with a magnetic resonance technique to identify the early stages of dementia, induced by D-galactose, and evaluate Simvastatin therapy." | 7.81 | Neuronal marker recovery after Simvastatin treatment in dementia in the rat brain: in vivo magnetic resonance study. ( Dubovický, M; Kašparová, S; Kucharská, J; Liptaj, T; Lipták, B; Sumbalová, Z; Szomolányi, P; Trattnig, S; Tušková, R; Uličná, O; Vančová, O, 2015) |
| "The purpose of this study was to determine cerebral myo-inositol (mI) in adults with Down syndrome (DS), and to trace the chronobiology of DS to Alzheimer disease (AD)." | 7.69 | Role of increased cerebral myo-inositol in the dementia of Down syndrome. ( Ross, BD; Shonk, T, 1995) |
| " The mean CSF concentration and the mean CSF/plasma concentration ratio of myo-inositol were significantly elevated in Down syndrome compared with controls, but were not correlated with the presence of dementia in the Down subjects." | 5.08 | Polyol profiles in Down syndrome. myo-Inositol, specifically, is elevated in the cerebrospinal fluid. ( Holloway, HW; Rapoport, SI; Schapiro, MB; Shetty, HU, 1995) |
| "Neurodegenerative dementias are characterized by elevated myoinositol and decreased N-acetylaspartate (NAA) levels." | 4.89 | Magnetic resonance spectroscopy in common dementias. ( Kantarci, K, 2013) |
| "The aim of study was to search for new biomarkers with a magnetic resonance technique to identify the early stages of dementia, induced by D-galactose, and evaluate Simvastatin therapy." | 3.81 | Neuronal marker recovery after Simvastatin treatment in dementia in the rat brain: in vivo magnetic resonance study. ( Dubovický, M; Kašparová, S; Kucharská, J; Liptaj, T; Lipták, B; Sumbalová, Z; Szomolányi, P; Trattnig, S; Tušková, R; Uličná, O; Vančová, O, 2015) |
| " Myo-inositol (mI), whose transporter gene is located on chromosome 21, has been associated with dementia in the non-DS population; however, nobody has contrasted brain mI in DS with (DS+) and without (DS-) dementia to other non-DS groups." | 3.77 | Down syndrome with and without dementia: an in vivo proton Magnetic Resonance Spectroscopy study with implications for Alzheimer's disease. ( Archer, N; Beacher, F; Daly, E; Foy, CML; Lamar, M; Lovestone, S; Morris, RG; Murphy, DGM; Murphy, KC; Poppe, M; Prasher, V; Simmons, A, 2011) |
| " Although changes in myo-inositol and creatine occur in the early stages of AD, abnormalities of N-acetyl aspartate do not occur in mild AD but progressively change with dementia severity." | 3.71 | Brain metabolite concentration and dementia severity in Alzheimer's disease: a (1)H MRS study. ( Alexander, GE; Chang, L; Huang, W; Krasuski, JS; Rapoport, SI; Schapiro, MB; Shetty, HU, 2001) |
| "The purpose of this study was to determine cerebral myo-inositol (mI) in adults with Down syndrome (DS), and to trace the chronobiology of DS to Alzheimer disease (AD)." | 3.69 | Role of increased cerebral myo-inositol in the dementia of Down syndrome. ( Ross, BD; Shonk, T, 1995) |
| "To evaluate cerebral biochemical abnormalities in patients with frontotemporal dementia and Alzheimer disease and to determine whether proton (hydrogen-1) magnetic resonance (MR) spectroscopy can help differentiate among these two patient groups and healthy (control) subjects." | 3.69 | Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy. ( Chang, L; Ernst, T; Mehringer, CM; Melchor, R, 1997) |
| "Dementia was an independent predictor of metabolite values." | 2.73 | Magnetic resonance spectroscopy performance for detection of dementia, Alzheimer's disease and mild cognitive impairment in a community-based survey. ( Antúnez, C; Carles, R; Fortuna, L; García Santos, JM; Gavrila, D; Jiménez Veiga, J; Navarro, C; Parrilla, G; Salmerón, D; Tormo, MJ; Torres del Río, S, 2008) |
| "Choline (Cho)/Cr was higher than normal in patients with AD, FTLD, and DLB." | 1.32 | 1H MR spectroscopy in common dementias. ( Boeve, BF; Edland, SD; Ferman, TJ; Ivnik, RJ; Jack, CR; Kantarci, K; Knopman, DS; O'Brien, PC; Petersen, RC; Smith, GE; Tang-Wai, DF; Tangalos, EG; Weigand, SD, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (12.00) | 18.7374 |
| 1990's | 4 (16.00) | 18.2507 |
| 2000's | 10 (40.00) | 29.6817 |
| 2010's | 7 (28.00) | 24.3611 |
| 2020's | 1 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Moccia, F | 1 |
| Negri, S | 1 |
| Faris, P | 1 |
| Angelone, T | 1 |
| Kantarci, K | 3 |
| Targosz-Gajniak, MG | 1 |
| Siuda, JS | 1 |
| Wicher, MM | 1 |
| Banasik, TJ | 1 |
| Bujak, MA | 1 |
| Augusciak-Duma, AM | 1 |
| Opala, G | 1 |
| Tušková, R | 1 |
| Lipták, B | 1 |
| Szomolányi, P | 1 |
| Vančová, O | 1 |
| Uličná, O | 1 |
| Sumbalová, Z | 1 |
| Kucharská, J | 1 |
| Dubovický, M | 1 |
| Trattnig, S | 1 |
| Liptaj, T | 1 |
| Kašparová, S | 1 |
| Almuqbel, M | 1 |
| Melzer, TR | 1 |
| Myall, DJ | 1 |
| MacAskill, MR | 1 |
| Pitcher, TL | 1 |
| Livingston, L | 1 |
| Wood, KL | 1 |
| Keenan, RJ | 1 |
| Dalrymple-Alford, JC | 1 |
| Anderson, TJ | 1 |
| Lin, AL | 1 |
| Powell, D | 1 |
| Caban-Holt, A | 1 |
| Jicha, G | 1 |
| Robertson, W | 1 |
| Gold, BT | 1 |
| Davis, R | 1 |
| Abner, E | 1 |
| Wilcock, DM | 1 |
| Schmitt, FA | 1 |
| Head, E | 1 |
| García Santos, JM | 1 |
| Gavrila, D | 1 |
| Antúnez, C | 1 |
| Tormo, MJ | 1 |
| Salmerón, D | 1 |
| Carles, R | 1 |
| Jiménez Veiga, J | 1 |
| Parrilla, G | 1 |
| Torres del Río, S | 1 |
| Fortuna, L | 1 |
| Navarro, C | 1 |
| Caserta, MT | 1 |
| Ragin, A | 1 |
| Hermida, AP | 1 |
| Ahrens, RJ | 1 |
| Wise, L | 1 |
| Pilatus, U | 1 |
| Lais, C | 1 |
| Rochmont, Adu M | 1 |
| Kratzsch, T | 1 |
| Frölich, L | 1 |
| Maurer, K | 1 |
| Zanella, FE | 1 |
| Lanfermann, H | 1 |
| Pantel, J | 1 |
| Lamar, M | 1 |
| Foy, CML | 1 |
| Beacher, F | 1 |
| Daly, E | 1 |
| Poppe, M | 1 |
| Archer, N | 1 |
| Prasher, V | 1 |
| Murphy, KC | 1 |
| Morris, RG | 1 |
| Simmons, A | 1 |
| Lovestone, S | 1 |
| Murphy, DGM | 1 |
| Weiss, U | 1 |
| Bacher, R | 1 |
| Vonbank, H | 1 |
| Kemmler, G | 1 |
| Lingg, A | 1 |
| Marksteiner, J | 1 |
| VIDAL-TEIXIDOR, R | 1 |
| GARCIA-BUNUEL, L | 1 |
| GARCIA-BUNUEL, M | 1 |
| Petersen, RC | 1 |
| Boeve, BF | 1 |
| Knopman, DS | 1 |
| Tang-Wai, DF | 1 |
| O'Brien, PC | 1 |
| Weigand, SD | 1 |
| Edland, SD | 1 |
| Smith, GE | 1 |
| Ivnik, RJ | 1 |
| Ferman, TJ | 1 |
| Tangalos, EG | 1 |
| Jack, CR | 1 |
| Frederick, BD | 1 |
| Lyoo, IK | 1 |
| Satlin, A | 1 |
| Ahn, KH | 1 |
| Kim, MJ | 1 |
| Yurgelun-Todd, DA | 1 |
| Cohen, BM | 1 |
| Renshaw, PF | 1 |
| Metastasio, A | 1 |
| Rinaldi, P | 1 |
| Tarducci, R | 1 |
| Mariani, E | 1 |
| Feliziani, FT | 1 |
| Cherubini, A | 1 |
| Pelliccioli, GP | 1 |
| Gobbi, G | 1 |
| Senin, U | 1 |
| Mecocci, P | 1 |
| Coulthard, E | 1 |
| Firbank, M | 1 |
| English, P | 1 |
| Welch, J | 1 |
| Birchall, D | 1 |
| O'Brien, J | 1 |
| Griffiths, TD | 1 |
| Garrard, P | 1 |
| Schott, JM | 1 |
| MacManus, DG | 1 |
| Hodges, JR | 1 |
| Fox, NC | 1 |
| Waldman, AD | 1 |
| Shonk, T | 1 |
| Ross, BD | 2 |
| Shetty, HU | 2 |
| Schapiro, MB | 2 |
| Holloway, HW | 1 |
| Rapoport, SI | 2 |
| Shonk, TK | 1 |
| Moats, RA | 1 |
| Gifford, P | 1 |
| Michaelis, T | 1 |
| Mandigo, JC | 1 |
| Izumi, J | 1 |
| Ernst, T | 1 |
| Chang, L | 2 |
| Melchor, R | 1 |
| Mehringer, CM | 1 |
| Huang, W | 1 |
| Alexander, GE | 1 |
| Krasuski, JS | 1 |
| Lourander, L | 1 |
| Ruikka, I | 1 |
| Rautakorpi, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Open Label Study for the Use of Tyrosine Kinase Inhibitors for Treatment of Cognitive Decline Due to Degenerative Dementias[NCT02921477] | Phase 1 | 150 participants (Anticipated) | Interventional | 2016-09-30 | Enrolling by invitation | ||
| Focused Ultrasound Delivery of Exosomes for Treatment of Refractory Depression, Anxiety, and Neurodegenerative Dementias[NCT04202770] | 300 participants (Anticipated) | Interventional | 2019-12-01 | Suspended (stopped due to Pending COVID-19 pandemic; pending status of product development) | |||
| An Open-label Exploratory Study With Memantine: Correlation Between Proton Magnetic Resonance Spectroscopy, Cerebrospinal Fluid Biomarkers, and Cognition in Patients With Mild to Moderate Alzheimer's Disease[NCT00551161] | Phase 4 | 12 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Ratios of myo-inositol (mI), N-acetylaspartate (NAA), total creatine (Cr), and choline (Cho) by single voxel 1H MRS (proton magnetic resonance spectroscopy). Mean (± SD) metabolite levels (normalized to T2-corrected water signal intensity) and metabolite ratios for Alzheimer's disease subjects at baseline (t0), after 24 weeks of ongoing monotherapy with stable-dose cholinesterase inhibitor (t1), and after another 24 weeks of combination therapy with memantine in addition to stable-dose cholinesterase inhibitor (t2). The Wilcoxon signed-rank test was used to examine whether the change between t0 and t1 differed from the change between t1 and t2 [(t2 - t1) - (t1 - t0)]. (NCT00551161)
Timeframe: Baseline, 24 weeks, and 48 weeks
| Intervention | ratio (normalized to T2-corrected water (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Change in NAA [(t2-t1) - (t1-t0)] | Change in Cr [(t2-t1) - (t1-t0)] | Change in Cho [(t2-t1) - (t1-t0)] | Change in mI [(t2-t1) - (t1-t0)] | Change in NAA/Cr [(t2-t1) - (t1-t0)] | Change in Cho/Cr [(t2-t1) - (t1-t0)] | Change in mI/Cr [(t2-t1) - (t1-t0)] | Change in NAA/Cho [(t2-t1) - (t1-t0)] | Change in NAA/mI [(t2-t1) - (t1-t0)] | |
| Memantine | -54 | -2 | 9 | 16 | -0.09 | 0.02 | 0.04 | -0.26 | -0.35 |
2 reviews available for inositol and Dementia
| Article | Year |
|---|---|
Proton MRS in mild cognitive impairment.
Topics: Alzheimer Disease; Animals; Aspartic Acid; Biomarkers; Brain; Choline; Cognitive Dysfunction; Creati | 2013 |
Magnetic resonance spectroscopy in common dementias.
Topics: Aspartic Acid; Biomarkers; Brain; Dementia; Humans; Inositol; Magnetic Resonance Spectroscopy | 2013 |
4 trials available for inositol and Dementia
| Article | Year |
|---|---|
Magnetic resonance spectroscopy performance for detection of dementia, Alzheimer's disease and mild cognitive impairment in a community-based survey.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain; Choline; Cognition Disorders; Crea | 2008 |
Polyol profiles in Down syndrome. myo-Inositol, specifically, is elevated in the cerebrospinal fluid.
Topics: Adult; Age Factors; Aged; Biomarkers; Dementia; Down Syndrome; Female; Gas Chromatography-Mass Spect | 1995 |
Probable Alzheimer disease: diagnosis with proton MR spectroscopy.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Brain Diseases, Metabolic; Creatine; Dementia; Diagno | 1995 |
Psychological methods applied to evaluate symptomatic geriatric treatment.
Topics: Aged; Clinical Trials as Topic; Dementia; Ethanol; Female; Geriatrics; Humans; Inositol; Kinesthesis | 1970 |
19 other studies available for inositol and Dementia
| Article | Year |
|---|---|
Targeting endothelial ion signalling to rescue cerebral blood flow in cerebral disorders.
Topics: Ankyrins; Cerebrovascular Circulation; Dementia; Endothelial Cells; Endothelium, Vascular; Humans; I | 2022 |
Magnetic resonance spectroscopy as a predictor of conversion of mild cognitive impairment to dementia.
Topics: Aged; Aged, 80 and over; Aspartic Acid; Brain; Choline; Cognitive Dysfunction; Creatine; Dementia; D | 2013 |
Magnetic resonance spectroscopy as a predictor of conversion of mild cognitive impairment to dementia.
Topics: Aged; Aged, 80 and over; Aspartic Acid; Brain; Choline; Cognitive Dysfunction; Creatine; Dementia; D | 2013 |
Magnetic resonance spectroscopy as a predictor of conversion of mild cognitive impairment to dementia.
Topics: Aged; Aged, 80 and over; Aspartic Acid; Brain; Choline; Cognitive Dysfunction; Creatine; Dementia; D | 2013 |
Magnetic resonance spectroscopy as a predictor of conversion of mild cognitive impairment to dementia.
Topics: Aged; Aged, 80 and over; Aspartic Acid; Brain; Choline; Cognitive Dysfunction; Creatine; Dementia; D | 2013 |
Neuronal marker recovery after Simvastatin treatment in dementia in the rat brain: in vivo magnetic resonance study.
Topics: Animals; Aspartic Acid; Biomarkers; Brain; Dementia; Dipeptides; Disease Models, Animal; Galactose; | 2015 |
Metabolite ratios in the posterior cingulate cortex do not track cognitive decline in Parkinson's disease in a clinical setting.
Topics: Aged; Aged, 80 and over; Aspartic Acid; Bayes Theorem; Case-Control Studies; Choline; Cognitive Dysf | 2016 |
(1)H-MRS metabolites in adults with Down syndrome: Effects of dementia.
Topics: Activities of Daily Living; Adult; Analysis of Variance; Aspartic Acid; Dementia; Down Syndrome; Fem | 2016 |
Single voxel magnetic resonance spectroscopy at 3 Tesla in a memory disorders clinic: early right hippocampal NAA/Cr loss in mildly impaired subjects.
Topics: Aged; Aspartic Acid; Choline; Creatine; Dementia; Female; Functional Laterality; Hippocampus; Humans | 2008 |
Conversion to dementia in mild cognitive impairment is associated with decline of N-actylaspartate and creatine as revealed by magnetic resonance spectroscopy.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Choline; Cognition; Cognition Disorders; Creatine; De | 2009 |
Down syndrome with and without dementia: an in vivo proton Magnetic Resonance Spectroscopy study with implications for Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain Chemistry; Case-Control Studies; Dementia; Down Syndro | 2011 |
Cognitive impairment: assessment with brain magnetic resonance imaging and proton magnetic resonance spectroscopy.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Brain Chemistry; Choline; Cognition Disorders; Creati | 2003 |
[On the treatment of depressive states in aged persons].
Topics: Dementia; Depression; Depressive Disorder; Humans; Inositol; Pentylenetetrazole; Psychotic Disorders | 1963 |
CEREBROSPINAL FLUID LEVELS OF FREE MYOINOSITOL IN SOME NEUROLOGICAL DISORDERS.
Topics: Biochemical Phenomena; Biochemistry; Cerebrospinal Fluid; Child; Dementia; Diabetic Neuropathies; Ge | 1965 |
1H MR spectroscopy in common dementias.
Topics: Acetylcholine; Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain; Brain Chemistry; Ch | 2004 |
In vivo proton magnetic resonance spectroscopy of the temporal lobe in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Aspartic Acid; Brain Mapping; Case | 2004 |
Conversion of MCI to dementia: Role of proton magnetic resonance spectroscopy.
Topics: Aged; Amnesia; Aspartic Acid; Cerebral Cortex; Choline; Cognition Disorders; Creatine; Dementia; Dis | 2006 |
Proton magnetic resonance spectroscopy in frontotemporal dementia.
Topics: Aged; Aspartic Acid; Biomarkers; Cerebral Cortex; Dementia; Female; Frontal Lobe; Gliosis; Gyrus Cin | 2006 |
Posterior cingulate neurometabolite profiles and clinical phenotype in frontotemporal dementia.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Atrophy; Dementia; Diagnosis, Differential; Female; Frontal | 2006 |
Role of increased cerebral myo-inositol in the dementia of Down syndrome.
Topics: Adolescent; Adult; Alzheimer Disease; Aspartic Acid; Brain; Child; Child, Preschool; Choline; Creati | 1995 |
Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Dementia; Discriminant Analysis; Female; | 1997 |
Brain metabolite concentration and dementia severity in Alzheimer's disease: a (1)H MRS study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Aspartic Acid; Brain; Choline; Cre | 2001 |